Analysts’ Viewpoint
Increase in prevalence of cardiovascular diseases (CVDs), including heart attack and stroke, is anticipated to augment the demand for antiplatelet drugs and consequently, boost the antiplatelet drugs market growth during the forecast period. Innovation in drug development is further fueling the antiplatelet drugs industry. Rapid growth in geriatric population, unhealthy lifestyles, obesity, and smoking are some of the major factors contributing to the growing incidence of CVDs. This factor is positively impacting the demand for antiplatelet drugs, thus driving market progress.
Additionally, rise in adoption of antiplatelet drugs in emerging economies is creating lucrative growth opportunities for market players. Moreover, various companies in the global market are focusing on innovative strategies, including strategic alliances and acquisitions, to gain revenue benefits.
Antiplatelet drugs are medications that inhibit the ability of platelets to clump together and form blood clots. Platelets play a key role in the blood clotting process, which is essential to prevent excessive bleeding after an injury. However, when platelets clump together inside blood vessels, they can also form blood clots. These can block blood flow to vital organs and lead to serious health issues such as heart attacks and strokes.
Antiplatelet drugs work by interfering with the activity of platelets, reducing their ability to stick together and form clots. There are several types of antiplatelet drugs, including aspirin, ADP receptor inhibitors, phosphodiesterase inhibitors, and glycoprotein IIb/IIIa inhibitors.
Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that is commonly used as an antiplatelet agent. It works by blocking the action of an enzyme called cyclooxygenase (COX), which is involved in the production of prostaglandins. Aspirin blocking COX and reduces the formation of thromboxane A2, which is a potent platelet activator. ADP receptor inhibitors are a class of antiplatelet drugs that work by blocking the P2Y12 receptor on the surface of platelets.
Phosphodiesterase inhibitors are a class of antiplatelet drugs that work by increasing the concentration of cyclic adenosine monophosphate (cAMP) in platelets. Glycoprotein IIb/IIIa inhibitors are a class of antiplatelet drugs that work by blocking the glycoprotein IIb/IIIa receptor on the surface of platelets.
Rise in global prevalence of cardiovascular diseases is a significant factor augmenting the demand for antiplatelet drugs. Cardiovascular diseases, such as heart attacks and strokes, are a leading cause of death worldwide. Rise in geriatric population, unhealthy lifestyles, and smoking habits are the main causes of cardiovascular diseases.
According to the WHO, cardiovascular diseases is the leading cause of death globally. As per estimation, around 17.9 million people died from CVDs in 2019, which represents 32.0% of total deaths, globally. Moreover, 85% of deaths occurred due to strokes and heart attacks.
Antiplatelet drugs play a key role in the prevention and treatment of cardiovascular diseases by reducing the risk of blood clots and subsequent events such as heart attacks and strokes. Therefore, demand for antiplatelet drugs is on the rise.
Key pharmaceutical manufacturers are engaged in making improvements in existing drugs to increase their efficacy, safety, and patient outcomes. Targeted and efficient drug delivery systems can help ensure that the drug reaches the intended site of action, reducing the risk of side-effects and increasing the effectiveness of the drug. For instance, drug-eluting stents, which slowly release an antiplatelet drug to prevent restenosis and blood clots in patients undergoing angioplasty, are an example of an innovative drug delivery system for antiplatelet drugs.
Development of new antiplatelet drugs is further creating incremental opportunities for market players. For instance, researchers at the University of Illinois Chicago (UIC) have created a novel medication that prevents blood clots without raising the risk of bleeding. Development of novel targets, such as new platelet receptors, or the use of new drug classes, such as monoclonal antibodies is gaining traction. Advances in technology, such as high-throughput screening and molecular modeling, can also aid in the discovery and development of new antiplatelet drugs.
According to the latest global market analysis, the irreversible cyclooxygenase (COX) inhibitors drug type segment dominated the global market in 2022 and held major antiplatelet drugs industry share.
Irreversible COX inhibitors, also known as aspirin-like drugs, irreversibly inhibit both COX-1 and COX-2 enzymes by acetylating a serine residue in the active site of the enzyme. This irreversible binding results in the permanent inhibition of the enzyme's activity. Aspirin is the most well-known irreversible COX inhibitor and is widely used as an anti-inflammatory and pain reliever. Other irreversible COX inhibitors include indomethacin, diclofenac, and ibuprofen. Increase in adoption of irreversible cyclooxygenase (COX) inhibitors is projected to fuel market expansion in the near future.
Based on the route of administration, the global antiplatelet drugs market has been divided into oral and injectable. The oral segment accounted for major share of the global market in 2022. The oral route is the most prescribed route of administration, as it is easy to administer, convenient, and provides a predictable absorption of antiplatelet drugs.
In terms of indication, the antiplatelet drugs market segmentation comprises myocardial infarction, percutaneous coronary intervention, arterial thrombosis, and angioplasty.
Myocardial Infarction (MI), also known as a heart attack, occurs when the blood supply to the heart muscle is blocked, usually by a blood clot, leading to damage to the heart tissue or even death. Percutaneous coronary intervention (PCI) is a minimally invasive procedure used to treat a blocked or narrowed coronary artery in order to restore blood flow to the heart muscle.
PCI is frequently performed in patients suffering from an acute myocardial infarction (AMI), because it can swiftly restore blood supply to the afflicted portion of the heart and avoid additional damage. Antiplatelet therapy is found to be effective for patients undergoing myocardial infarction (MI) or percutaneous coronary intervention (PCI).
In terms of distribution channel, the global market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies distribution channel segment accounted for major share in 2022, and it is likely to dominate the global antiplatelet drugs market during the forecast period.
Rise in availability of prescribed oral drugs in hospital pharmacies is a major factor augmenting the segment. This is likely to fuel market value of antiplatelet drugs in the next few years.
North America accounted for major share of the global market in 2022. The market is likely to maintain its dominance during the forecast period due to the rise in prevalence of chronic diseases in the region. According to the Centers for Disease Control and Prevention (CDC), every six in 10 adults are suffering from chronic diseases. Moreover, chronic diseases including diabetes, cancer, and heart diseases are considered to be the major causes of mortality and disability in the U.S. The antiplatelet drugs market size in North America is likely to increase in the near future, owing to the rise in healthcare expenditure in the region.
The Asia Pacific market is anticipated to expand at a rapid pace in the next few years. Increase in incidence of noncommunicable diseases (NCDs) in the region is contributing to antiplatelet drugs market development.
According to the latest antiplatelet drugs market trends, the global industry is fragmented, with the presence of large number of local as well as international players. Market players are gaining lucrative antiplatelet drugs business opportunities by implementing various strategies such as the expansion of product portfolio, mergers, and acquisitions.
Leading players in the global market are Alta Laboratories, AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim, Pharmaceuticals, Bristol-Myers Squibb Company, F. Hoffmann La Roche, Mylan Pharmaceuticals, Pharmascience, Portola Pharmaceuticals, Sandoz Canada Incorporated, Sanis Health, Shandong Xinhua Pharmaceutical, Syntex, Teva Pharmaceuticals, and The Medicines Company.
Key players have been profiled in the antiplatelet drugs market report based on parameters such as company overview, business strategies, business segments, recent developments, financial overview, and product portfolio.
|
Attribute |
Detail |
|
Market Size Value in 2022 |
US$ 2.1 Bn |
|
Market Forecast Value in 2031 |
US$ 4.1 Bn |
|
Growth Rate (CAGR) |
7.5% |
|
Forecast Period |
2023–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global market was valued at US$ 2.1 Bn in 2022
It is projected to reach more than US$ 4.1 Bn by 2031
The CAGR is likely to be 7.5% from 2023 to 2031
Growth in prevalence of cardiovascular diseases and innovation in drug development
North America is expected to account for major share during the forecast period
Alta Laboratories, AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb Company, F. Hoffmann La Roche, Mylan Pharmaceuticals, Pharmascience, Portola Pharmaceuticals, Sandoz Canada Incorporated, Sanis Health, Shandong Xinhua Pharmaceutical, Syntex, Teva Pharmaceuticals, and The Medicines Company
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Antiplatelet Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Antiplatelet Drugs Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Product/Brand Analysis
5.2. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
5.3. Disease Prevalence & Incidence Rate globally with key countries
5.4. Pipeline Analysis
6. Global Antiplatelet Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Type, 2017-2031
6.3.1. Irreversible Cyclooxygenase (COX) Inhibitors
6.3.2. Adenosine Diphosphate (ADP) Receptor Inhibitors
6.3.3. Glycoprotein IIb/IIIa Inhibitors
6.3.4. Adenosine Reuptake Inhibitors
6.3.5. Thromboxane Inhibitors and Phosphodiesterase Inhibitors
6.4. Market Attractiveness, by Drug Type
7. Global Antiplatelet Drugs Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017-2031
7.3.1. Myocardial Infarction
7.3.2. Percutaneous Coronary Intervention
7.3.3. Arterial Thrombosis
7.3.4. Angioplasty
7.4. Market Attractiveness, by Indication
8. Global Antiplatelet Drugs Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017-2031
8.3.1. Oral
8.3.2. Injectable
8.4. Market Attractiveness, by Route of Administration
9. Global Antiplatelet Drugs Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness, by Distribution Channel
10. Global Antiplatelet Drugs Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Country/Region
11. North America Antiplatelet Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2017-2031
11.2.1. Irreversible Cyclooxygenase (COX) Inhibitors
11.2.2. Adenosine Diphosphate (ADP) Receptor Inhibitors
11.2.3. Glycoprotein IIB/IIIA Inhibitors
11.2.4. Adenosine Reuptake Inhibitors
11.2.5. Thromboxane Inhibitors and Phosphodiesterase Inhibitors
11.3. Market Value Forecast, by Indication, 2017-2031
11.3.1. Myocardial Infarction
11.3.2. Percutaneous Coronary Intervention
11.3.3. Arterial Thrombosis
11.3.4. Angioplasty
11.4. Market Value Forecast, by Route of Administration, 2017-2031
11.4.1. Oral
11.4.2. Injectable
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Indication
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Antiplatelet Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017-2031
12.2.1. Irreversible Cyclooxygenase (COX) Inhibitors
12.2.2. Adenosine Diphosphate (ADP) Receptor Inhibitors
12.2.3. Glycoprotein IIB/IIIA Inhibitors
12.2.4. Adenosine Reuptake Inhibitors
12.2.5. Thromboxane Inhibitors and Phosphodiesterase Inhibitors
12.3. Market Value Forecast, by Indication, 2017-2031
12.3.1. Myocardial Infarction
12.3.2. Percutaneous Coronary Intervention
12.3.3. Arterial Thrombosis
12.3.4. Angioplasty
12.4. Market Value Forecast, by Route of Administration, 2017-2031
12.4.1. Oral
12.4.2. Injectable
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Indication
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Antiplatelet Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2017-2031
13.2.1. Irreversible Cyclooxygenase (COX) Inhibitors
13.2.2. Adenosine Diphosphate (ADP) Receptor Inhibitors
13.2.3. Glycoprotein IIB/IIIA Inhibitors
13.2.4. Adenosine Reuptake Inhibitors
13.2.5. Thromboxane Inhibitors and Phosphodiesterase Inhibitors
13.3. Market Value Forecast, by Indication, 2017-2031
13.3.1. Myocardial Infarction
13.3.2. Percutaneous Coronary Intervention
13.3.3. Arterial Thrombosis
13.3.4. Angioplasty
13.4. Market Value Forecast, by Route of Administration, 2017-2031
13.4.1. Oral
13.4.2. Injectable
13.5. Market Value Forecast, by Distribution Channel, 2017-2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Indication
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Antiplatelet Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2017-2031
14.2.1. Irreversible Cyclooxygenase (COX) Inhibitors
14.2.2. Adenosine Diphosphate (ADP) Receptor Inhibitors
14.2.3. Glycoprotein IIB/IIIA Inhibitors
14.2.4. Adenosine Reuptake Inhibitors
14.2.5. Thromboxane Inhibitors and Phosphodiesterase Inhibitors
14.3. Market Value Forecast, by Indication, 2017-2031
14.3.1. Myocardial Infarction
14.3.2. Percutaneous Coronary Intervention
14.3.3. Arterial Thrombosis
14.3.4. Angioplasty
14.4. Market Value Forecast, by Route of Administration, 2017-2031
14.4.1. Oral
14.4.2. Injectable
14.5. Market Value Forecast, by Distribution Channel, 2017-2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Indication
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Antiplatelet Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Type, 2017-2031
15.2.1. Irreversible Cyclooxygenase (COX) Inhibitors
15.2.2. Adenosine Diphosphate (ADP) Receptor Inhibitors
15.2.3. Glycoprotein IIB/IIIA Inhibitors
15.2.4. Adenosine Reuptake Inhibitors
15.2.5. Thromboxane Inhibitors and Phosphodiesterase Inhibitors
15.3. Market Value Forecast, by Indication, 2017-2031
15.3.1. Myocardial Infarction
15.3.2. Percutaneous Coronary Intervention
15.3.3. Arterial Thrombosis
15.3.4. Angioplasty
15.4. Market Value Forecast, by Route of Administration, 2017-2031
15.4.1. Oral
15.4.2. Injectable
15.5. Market Value Forecast, by Distribution Channel, 2017-2031
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Drug Type
15.7.2. By Indication
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Share/Ranking Analysis By Company (2022)
16.3. Company Profiles
16.3.1. Alta Laboratories
16.3.1.1. Company Overview
16.3.1.2. Drug Type Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Strategic Overview
16.3.2. AstraZeneca
16.3.2.1. Company Overview
16.3.2.2. Drug Type Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Strategic Overview
16.3.3. Bayer Pharmaceuticals
16.3.3.1. Company Overview
16.3.3.2. Drug Type Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Strategic Overview
16.3.4. Boehringer Ingelheim Pharmaceuticals
16.3.4.1. Company Overview
16.3.4.2. Drug Type Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Strategic Overview
16.3.5. Bristol-Myers Squibb Company
16.3.5.1. Company Overview
16.3.5.2. Drug Type Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Strategic Overview
16.3.6. F. Hoffmann La Roche
16.3.6.1. Company Overview
16.3.6.2. Drug Type Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Strategic Overview
16.3.7. Mylan Pharmaceuticals
16.3.7.1. Company Overview
16.3.7.2. Drug Type Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Strategic Overview
16.3.8. Pharmascience
16.3.8.1. Company Overview
16.3.8.2. Drug Type Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Strategic Overview
16.3.9. Portola Pharmaceuticals
16.3.9.1. Company Overview
16.3.9.2. Drug Type Portfolio
16.3.9.3. SWOT Analysis
16.3.9.4. Strategic Overview
16.3.10. Sandoz Canada Incorporated
16.3.10.1. Company Overview
16.3.10.2. Drug Type Portfolio
16.3.10.3. SWOT Analysis
16.3.10.4. Strategic Overview
16.3.11. Sanis Health
16.3.11.1. Company Overview
16.3.11.2. Drug Type Portfolio
16.3.11.3. SWOT Analysis
16.3.11.4. Strategic Overview
16.3.12. Shandong Xinhua Pharmaceutical
16.3.12.1. Company Overview
16.3.12.2. Drug Type Portfolio
16.3.12.3. SWOT Analysis
16.3.12.4. Strategic Overview
16.3.13. Syntex
16.3.13.1. Company Overview
16.3.13.2. Drug Type Portfolio
16.3.13.3. SWOT Analysis
16.3.13.4. Strategic Overview
16.3.14. Teva Pharmaceuticals
16.3.14.1. Company Overview
16.3.14.2. Drug Type Portfolio
16.3.14.3. SWOT Analysis
16.3.14.4. Strategic Overview
16.3.15. The Medicines Company
16.3.15.1. Company Overview
16.3.15.2. Drug Type Portfolio
16.3.15.3. SWOT Analysis
16.3.15.4. Strategic Overview
List of Tables
Table 01: Global Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 02: Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 03: Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 04: Global Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 05: Global Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 08: North America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 09: North America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 10: North America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 11: Europe Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 12: Europe Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 13: Europe Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 14: Europe Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 15: Europe Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Asia Pacific Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 18: Asia Pacific Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 19: Asia Pacific Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 20: Asia Pacific Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Latin America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 23: Latin America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 24: Latin America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 25: Latin America Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 26: Middle East & Africa Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 28: Middle East & Africa Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017‒2031
Table 29: Middle East & Africa Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Indication, 2017‒2031
Table 30: Middle East & Africa Antiplatelet Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Antiplatelet Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Antiplatelet Drugs Market Value Share, by Drug Type, 2022
Figure 03: Global Antiplatelet Drugs Market Value Share, by Route of Administration, 2022
Figure 04: Global Antiplatelet Drugs Market Value Share, by Indication, 2022
Figure 05: Global Antiplatelet Drugs Market Value Share, by Distribution Channel, 2022
Figure 06 Global Antiplatelet Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 07: Global Antiplatelet Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
Figure 08: Global Antiplatelet Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 09: Global Antiplatelet Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 10: Global Antiplatelet Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 11: Global Antiplatelet Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 12: Global Antiplatelet Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 13: Global Antiplatelet Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 14: Global Antiplatelet Drugs Market Value Share Analysis, by Region, 2022 and 2031
Figure 15: Global Antiplatelet Drugs Market Attractiveness Analysis, by Region, 2023-2031
Figure 16: North America Antiplatelet Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 17: North America Antiplatelet Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 18: North America Antiplatelet Drugs Market Attractiveness Analysis, by Country, 2023-2031
Figure 19: North America Antiplatelet Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 20: North America Antiplatelet Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
Figure 21: North America Antiplatelet Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 22: North America Antiplatelet Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 23: North America Antiplatelet Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 24: North America Antiplatelet Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 25: North America Antiplatelet Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 26: North America Antiplatelet Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 27: Europe Antiplatelet Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 28: Europe Antiplatelet Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 29: Europe Antiplatelet Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 30: Europe Antiplatelet Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 31: Europe Antiplatelet Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
Figure 32: Europe Antiplatelet Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 33: Europe Antiplatelet Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 34: Europe Antiplatelet Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 35: Europe Antiplatelet Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 36: Europe Antiplatelet Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 37: Europe Antiplatelet Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 38: Asia Pacific Antiplatelet Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 39: Asia Pacific Antiplatelet Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 40: Asia Pacific Antiplatelet Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 41: Asia Pacific Antiplatelet Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 42: Asia Pacific Antiplatelet Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
Figure 43: Asia Pacific Antiplatelet Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 44: Asia Pacific Antiplatelet Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 45: Asia Pacific Antiplatelet Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 46: Asia Pacific Antiplatelet Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 47: Asia Pacific Antiplatelet Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 48: Asia Pacific Antiplatelet Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 49: Latin America Antiplatelet Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 50: Latin America Antiplatelet Drugs Market Value Share Analysis, by Country/Sub-Region, 2022 and 2031
Figure 51: Latin America Antiplatelet Drugs Market Attractiveness Analysis, by Country/Sub-Region, 2022-2031
Figure 52: Latin America Antiplatelet Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 53: Latin America Antiplatelet Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
Figure 54: Latin America Antiplatelet Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 55: Latin America Antiplatelet Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 56: Latin America Antiplatelet Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 57: Latin America Antiplatelet Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 58: Latin America Antiplatelet Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 59: Latin America Antiplatelet Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 60: Middle East & Africa Antiplatelet Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 61: Middle East & Africa Antiplatelet Drugs Market Value Share Analysis, by Country/Sub-Region, 2022 and 2031
Figure 62: Middle East & Africa Antiplatelet Drugs Market Attractiveness Analysis, by Country/Sub-Region, 2022-2031
Figure 63: Middle East & Africa Antiplatelet Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 64: Middle East & Africa Antiplatelet Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
Figure 65: Middle East & Africa Antiplatelet Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 66: Middle East & Africa Antiplatelet Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 67: Middle East & Africa Antiplatelet Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 68: Middle East & Africa Antiplatelet Drugs Market Attractiveness Analysis, by Indication, 2023-2031
Figure 69: Middle East & Africa Antiplatelet Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 70: Middle East & Africa Antiplatelet Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 71: Company Share Analysis, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Antiplatelet Drugs Market
*86 figures and 60 tables includes